TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
|Articles|November 1, 2012
White House Won't Oppose New Challenge to 2010 Healthcare Law
Advertisement
The Obama administration on Wednesday cleared the way for the U.S. Supreme Court to revive a lawsuit that challenges the 2010 healthcare overhaul on religious grounds, including a claim that it helps fund abortions.
Liberty University, a Christian college in Lynchburg, Virginia, had challenged the individual mandate, which required Americans to obtain insurance by 2014 or pay a penalty, and a mandate requiring big employers to provide coverage for workers.
Read the full story:
Source: Reuters
Advertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
4
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
5